Actively Recruiting
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
Led by Sanofi · Updated on 2025-08-13
150
Participants Needed
11
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prurigo nodularis (PN) is a skin disease characterized by the presence of single to multiple symmetrically distributed, intensively itching nodules. The main symptom is uncontrollable itching leading to prolonged, repetitive, and uncontrollable rubbing, scratching which in turn causes injuries to the skin. In recent years, number of studies evaluating PN, the affected population and the disease burden has increased but PN remains still understudied. This non-interventional study is intended to describe the long-term effectiveness of dupilumab (Dupixent®) in participants aged 18 years or older and suffering from moderate-to-severe PN who receive dupilumab for PN treatment in a real-world setting in Germany according to the prescribing information (Summary of Product Characteristics \[SmPC\]). The decision to initiate dupilumab treatment is made by the treating physician and participant according to the participant's medical need and to the standard of best medical practice. This decision is made independently and before data inclusion in this non-interventional study.
CONDITIONS
Official Title
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants at least 18 years of age at baseline visit
- Signed written informed consent
- New initiation with dupilumab or treatment started within last 7 days for moderate to severe prurigo nodularis as per prescribing information
- Patients with a confirmed diagnosis of prurigo nodularis
You will not qualify if you...
- Contraindication to dupilumab according to current prescribing information
- Treated with dupilumab for more than 7 days
- Any acute or chronic condition limiting ability to complete questionnaires or participate, as judged by treating physician
- Participation in another ongoing interventional or observational study that may influence assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Investigational Site Number: 013
Adernach, Germany, 56626
Actively Recruiting
2
Investigational site number: 001
Berlin, Germany, 12203
Actively Recruiting
3
Investigational Site Number: 002
Berlin, Germany, 13507
Actively Recruiting
4
Investigational Site Number: 023
Chemnitz, Germany, 09117
Actively Recruiting
5
Investigational Site Number: 005
Düren, Germany, 52349
Actively Recruiting
6
Investigational Site Number: 004
Düsseldorf, Germany, 40219
Actively Recruiting
7
Investigational Site Number: 007
Hamburg, Germany, 22391
Actively Recruiting
8
Investigational Site Number: 016
Leipzig, Germany, 04371
Actively Recruiting
9
Investigational Site Number: 031
Mainz, Germany, 55128
Actively Recruiting
10
Investigational Site Number: 022
Potsdam, Germany, 14467
Actively Recruiting
11
Investigational Site Number: 024
Potsdam, Germany, 14469
Actively Recruiting
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here